Skip to content
CancerIndex

Publication

Exploratory immunomonitoring during radiochemotherapy in HNSCC and machine-learning reveal immune parameters associated with disease-free survival.

Anna-Jasmina Donaubauer, Oliver Tomic, Lia Mogge, Sarina K Müller, Cecilia Marie Futsaether, Kristian Hovde Liland, Bao Ngoc Huynh, Jens von der Grün, Panagiotis Balermpas, Max Fleischmann, Matthias G Hautmann, Felix Steger, Christopher Bohr, Thomas Hehr, Carmen Stromberger, Volker Budach, Markus Schymalla, Rita Engenhart-Cabillic, Lukas Kocik, Hans Geinitz, Ursula Nestle, Gunter Klautke, Claudia Scherl, Philipp Schubert, Stefanie Corradini, Rainer Fietkau, Udo S Gaipl, Benjamin Frey, Marlen Haderlein

NPJ precision oncologyAug 31, 2026PMID 42675144doi:10.1038/s41698-026-01658-w PMC13530257Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Immunological biomarkers are increasingly relevant for personalized cancer treatment, but peripheral blood-derived biomarkers are not yet used to guide therapy in head and neck squamous cell carcinoma (HNSCC). The prospective non-randomized DIREKHT study (ClinicalTrials.gov: NCT02528955,…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 1

Registered trialsNCT02528955

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.